TY - JOUR AU - Wu, Yi-Long AU - Wang, Chang-Li AU - Liao, Mei-Lin AU - Guan, Zhong-Zhen AU - Gao, Chen-Yan AU - Lu, Shun AU - Zhao, Ming- Fang AU - Wang, Jie AU - Liu, Xiao-Qing AU - Yang, Jin-Ji AU - Liang, Jun AU - Mao, Wei-Min AU - Han, Bao-Hui AU - Zhang, Xu- Chao AU - Song, Yong AU - Feng, Ji-Feng AU - Ma, Sheng-Lin AU - Wu, Gang AU - Zhou, Cai-Cun AU - Chen, Ke-Neng AU - Cheng, Ying AU - He, Yong AU - Chen, Chun AU - Wang, Qun AU - Lin, Ji-Zhen AU - Zhu, Bo AU - Liu, Yun-Peng AU - Hu, Yi AU - Qiao, Gui-Bin AU - Zhou, Qing AU - Song, Qi-Bin AU - Wu, Nan AU - Wu, Lin AU - Huang, Cheng AU - Fu, Xiao-Long AU - Xiong, Jian-Ping AU - Hu, Jie AU - Hu, Cheng-Ping AU - Chang, Jian-Hua AU - Zhao, Qiong AU - Zhao, Jun AU - Zhou, Peng- Hui AU - Ma, Zhi-Yong AU - Chen, Yuan AU - Zhang, He-Long AU - Yang, Fan AU - Wang, Jian-Jun AU - Pan, Yue-Yin AU - Yang, Xue-Ning AU - Fan, Yun AU - Liu, Zhe AU - Fan, Wen AU - Yang, Nong AU - Guan, Yan-Fang AU - Sun, Hao AU - Zhong, Wen-Zhao PY - 2018 TI - A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel JF - Translational Lung Cancer Research; Vol 7, No 3 (June 14, 2018): Translational Lung Cancer Research (Lung Cancer Screening) Y2 - 2018 KW - N2 - The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades. UR - https://tlcr.amegroups.org/article/view/21690